What guidance did Pharming Group's management provide for the next earnings period?

What does Pharming Group do and what are its main business segments?

Did Pharming Group beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Pharming Group next quarter?

What were the key takeaways from Pharming Group's earnings call?

What factors drove the changes in Pharming Group's revenue and profit?

What were the key takeaways from Pharming Group’s earnings call?

What is the revenue and EPS growth rate for Pharming Group year over year?

- **Revenue Growth**: 27% YoY in 2025, driven by RUCONEST (26%) and Joenja (29%). 2026 guidance: $405-425 million (8-13% growth).
- **Joenja Momentum**: 120 U.S. patients on therapy, 40 new diagnoses in 2025. 52 eligible for pediatric label, 80+ on early access globally.
- **Pipeline Progress**: Leniolisib Phase II trials completed, napazimone pivotal study on track for 2027 readout. Japan Joenja NDA recommended for approval.
- **Financial Discipline**: 2026 R&D investment >$60 million, operating expenses growth 6-8%. Gross margin expected to improve to 90%.
- **Key Catalysts**: Joenja pediatric label, international launches, and pipeline data readouts in 2026-2027.

**【CEO Opening Remarks】**
- Total revenue grew 27% YoY in 2025, driven by 26% growth in RUCONEST and 29% in Joenja.
- Operating profit turned positive at $26 million, up from a loss in 2024. Operating cash flow reached $55 million.
- 2026 revenue guidance: $405-425 million (8-13% growth), with RUCONEST and Joenja as key growth engines.
- Pipeline highlights: leniolisib Phase II trials for broader PID indications and napazimone pivotal study for mitochondrial diseases.

**【Chief Commercial Officer (Leverne Marsh) Commentary】**
- **RUCONEST**: 26% global revenue growth in 2025, 9% Q4 growth despite new competitors. U.S. volume up 20%, with 60+ new enrollments in Q4. Patients returning to RUCONEST after trying oral therapies due to its reliability.
- **Joenja**: 53% Q4 growth, $58 million annual revenue. U.S. patients on therapy: 120 (25% YoY increase). 40 new APDS diagnoses in 2025. International expansion: U.K. launch success, 80+ patients on early access globally.
- Pediatric Joenja label extension in U.S. expected to drive future growth, with 52 eligible patients already identified.

**【Chief Medical Officer (Anurag Relan) Commentary】**
- **Joenja Pipeline**: Leniolisib Phase II trials for broader PID indications (CVID, VUS reclassification) completed enrollment, data readout Q4 2026. Napazimone pivotal study for mitochondrial diseases on track for 2027 readout.
- FDA Type A meeting scheduled for March to address Joenja pediatric label extension feedback.
- Japan NDA for Joenja in children 4-11 years recommended for approval, pending PMDA decision.

**【CFO Financial Commentary】**
- Q4 2025 revenue: $106.5 million (15% YoY growth). Joenja annual revenue exceeded $50 million, triggering $5 million milestone payment.
- Full-year 2025: $376.1 million revenue (27% YoY), $36.4 million adjusted operating profit. Gross margin stable at 88%.
- 2026 guidance: $330-335 million operating expenses (6-8% YoY growth), with >$60 million R&D investment. Gross margin expected to improve to 90%.
- Cash position: $181 million at year-end, up $12.2 million QoQ, driven by operating cash flow.

**【Q&A Highlights】**
- **Joenja Growth Split**: ~70-75% of 2026 growth expected from U.S., rest from international markets.
- **Patient Conversion**: 61 eligible U.S. patients for Joenja pediatric label; 1/3 already on early access. Conversion rate depends on FDA approval timing.
- **RUCONEST Dynamics**: Patients returning to RUCONEST after oral therapies due to its rapid onset and reliability in high-frequency attack patients.
- **M&A Strategy**: Open to value-accretive opportunities to expand pipeline, but no urgency.
- **Inventory Impact**: Q1 2026 RUCONEST growth may be 7-9% YoY lower due to inventory drawdown, but mid-single-digit growth expected for the year.

Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: 30% YoY growth to $97.3M, driven by RUCONEST (+29%) and Joenja (+35%).
- **Pediatric Growth**: 54 U.S. pediatric Joenja patients identified, 1/3 on early access ahead of Jan 2026 launch.
- **Pipeline Momentum**: Upgraded 2025 guidance to $365-$375M, with KL1333 on track for 2027 readout.
- **Financial Discipline**: 4x operating profit growth to $16M, cash flow $32M, and G&A reduction to optimize capital allocation.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue increased 30% YoY to $97.3 million, driven by 29% growth in RUCONEST and 35% growth in Joenja. Operating profit rose 4x to $16 million, and cash flow reached $32 million.
- **Product Performance**: RUCONEST revenue of $82 million reflects 28% vial volume growth, while Joenja's $15.1 million reflects 25% patient growth. Pediatric Joenja launch in the U.S. is expected in January 2026 with 54 identified patients (1/3 on early access).
- **Pipeline & Strategy**: Upgraded 2025 revenue guidance to $365-$375 million (23%-26% growth). Exiting non-sustainable RUCONEST markets in Europe to focus on high-growth initiatives. New CFO emphasizes financial discipline and capital allocation.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q3 gross profit $90.2 million (33% YoY growth), gross margin 93% (up from 91% in 2024). Year-to-date cash flow $44 million. Operating expenses +4% YoY (excluding Abliva costs).
- **Guidance**: Full-year 2025 revenue $365-$375 million, operating expenses $304-$308 million. Cash position restored to pre-Abliva levels ($168.9 million).

**【Q&A Key Highlights】**
- **RUCONEST Competition**: No pressure from oral therapies; serves severe HAE patients needing single-dose efficacy. New prescribers +22 QoQ.
- **Joenja Expansion**: U.K. launch progressing; U.S. pediatric label expected Jan 2026. 270 APDS patients in U.S., 13 new Q3. VUS reclassification could expand APDS prevalence by 50%.
- **Pipeline Progress**: KL1333 (mitochondrial disease) on track for 2027 readout. Joenja's real-world data shows infection reduction and quality-of-life improvement.
- **Capital Allocation**: No immediate M&A plans; focused on pipeline and commercial growth. G&A reduction saves costs for high-growth initiatives.

Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 26% YoY to $93.2M, guided to $335-350M (13-18% growth).
- **Product Momentum**: RUCONEST +28%, Joenja +15%; 18 new Joenja patients in H1 vs. 12 in 2024.
- **Pipeline Expansion**: Joenja targeting 20x larger PID/CVID populations, KL1333 pivotal study reactivated.
- **APDS Opportunity**: 100x higher prevalence suggested, 20% of 1,400 VUS patients to reclassify in H2.
- **Financial Strength**: $130.8M cash, 15% G&A reduction plan underway.

**【CEO Opening Remarks】**
- Q2 2025 total revenue grew 26% YoY to $93.2 million, driven by 28% growth in RUCONEST and 15% in Joenja.
- Operating profit of $12.9 million vs. loss of $3.1 million in Q2 2024, excluding $2.1M Abliva-related expenses.
- Raised 2025 revenue guidance to $335-350M (13-18% growth), up from $325-340M.
- Highlighted RUCONEST's 10-year market leadership and Joenja's APDS patient acceleration (18 new patients in H1 vs. 12 in 2024).

**【CCO Update on Products】**
- **RUCONEST**: 21 new prescribers added per quarter, 27% U.S. patient volume growth, 97% attack resolution rate.
- **Joenja**: 12.8M net revenue in Q2, 18 new patients in H1 (vs. 12 in 2024), U.K. launch with 185 global access program patients.
- APDS reclassification of 20% of 1,400 VUS patients expected in H2, pediatric label expansion in H2 2026.

**【CMO Pipeline Update】**
- **Joenja Expansion**: Phase II trials in PID with immune dysregulation (2,500+ U.S. patients) and CVID (13,000+ U.S. patients).
- **KL1333**: Pivotal study reactivated, 2027 readout for mitochondrial disease.
- **APDS Prevalence**: Cell study suggests 100x higher prevalence, broader clinical phenotype under investigation.

**【CFO Financial Commentary】**
- Q2 gross profit $84.2M (+27%), operating expenses $30.4-30.8M for 2025 (flat YoY + Abliva costs).
- Cash balance $130.8M at end of Q2, up $22.9M from Q1, driven by operating cash flow.
- 15% G&A expense reduction plan underway to offset $5.3M FX headwind.

**【Q&A Highlights】**
- **VUS Reclassification**: 20% of 1,400 U.S. patients expected to convert to paid therapy over time, no direct revenue impact until 2026.
- **RUCONEST Competition**: Sebetralstat targeting mild patients; RUCONEST's 97% attack resolution in severe cases maintains share.
- **Joenja Revenue Lag**: Q2 2024 stockpiling skewed comparison, current conversion rates unchanged.
- **KL1333 Milestone**: $5M payment due in 2025 for regulatory progress.


Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 revenue up 42% YoY to $89.1M, driven by 49% RUCONEST growth and 9% Joenja expansion.
- **Pipeline Momentum**: Joenja targeting 40x larger PID/CVID population; KL1333 mitochondrial disease trial on track for 2027 readout.
- **Cost Optimization**: $10M annual G&A reduction announced to support disciplined capital allocation.
- **Tariff Mitigation**: Proactively evaluating supply chain adjustments to minimize potential U.S. import tariffs.
- **VUS Patients**: 1,300 U.S. patients with uncertain variants expected to be reclassified as APDS in late 2025, fueling new patient growth.

**【CEO Opening Remarks】**
- Q1 2025 total revenue increased 42% YoY to $89.1 million, driven by 49% growth in RUCONEST ($68.6M) and 9% growth in Joenja ($10.5M). 
- Operating loss narrowed significantly YoY, with a profit of $0.8M excluding one-time Abliva acquisition costs.
- Full year 2025 guidance raised to $325-340M (prev $315-335M), reflecting strong pipeline momentum.
- Announced $10M annual G&A expense reduction to optimize capital allocation.

**【CCO Stephen Toor - Product Performance】**
- RUCONEST: 49% YoY growth due to new patient enrollment (+6 in Q1) and reduced specialty pharmacy destocking. 97% attack resolution rate in single dose.
- Joenja: 9% YoY growth with 102 U.S. patients on therapy (vs 96 in Q4 2024). 6 new U.S. patients added in Q1, highest quarterly increase since Q2 2024.
- Key growth drivers: VUS reclassification, pediatric label expansion, and international launches (e.g., U.K.).

**【CMO Anurag Relan - Pipeline Updates】**
- Joenja: Phase II trials for PID and CVID underway, targeting 40x larger patient population. Pediatric label expansion expected in 2026.
- KL1333: Registration-enabling trial for mitochondrial diseases with 2027 readout and potential 2028 approval.
- VUS program: 1,300 U.S. patients with uncertain genetic variants being reclassified, with results expected late 2025.

**【CFO Jeroen Wakkerman - Financial Highlights】**
- Q1 2025 GAAP net loss: $14.9M (vs $2.1M profit in Q1 2024), driven by $7.8M Abliva acquisition costs.
- Operating cash flow positive for 3rd consecutive quarter, with $108.9M cash on hand post-Abliva purchase.
- 2025 OpEx guidance: Flat vs 2024 ($265-275M) excluding $30M Abliva-related costs.

**【Q&A Key Takeaways】**
- Tariff mitigation: Exploring supply chain adjustments, but no immediate impact expected.
- Joenja net pricing: ~75% gross-to-net flow through, stable vs 2024 levels.
- VUS patient conversion: Expect accelerated new patient additions in H2 2025.
- Tax impact: Q1 2025 tax expense was one-time due to Abliva costs; normalized rate expected for remainder of year.


Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

- **Revenue Growth Surpasses Expectations**: 21% YoY to $297 million, driven by RUCONEST (+11%) and Joenja (+147%).
- **Joenja Expansion**: 65% Q4 growth, 96 US patients on therapy, and 2026 pediatric label launch.
- **RUCONEST Resilience**: 9% Q4 growth, 97% attack resolution rate, positioned as "go-to" for severe HAE patients.
- **Pipeline Expansion**: $30 million 2025 spend on Abliva integration, Phase 2 trials for CVID and mitochondrial disease.
- **2025 Outlook**: $315-335 million revenue guidance, 6-13% growth, with Joenja acceleration post-VUS resolution.


**【CEO Opening Remarks】**
- Full-year 2024 revenue grew 21% to $297 million, exceeding guidance, driven by RUCONEST (+11%) and Joenja (+147%).
- RUCONEST Q4 sales reached $79.8 million, up 9% YoY, with 24% new patient enrollment growth.
- Joenja achieved $13.1 million in Q4, up 66% YoY, with 96 patients on US therapy and 188 global access program patients.
- Abliva acquisition completed for $66.1 million, adding KL1333 for mitochondrial diseases.
- 2025 revenue guidance: $315-335 million (6-13% growth), with RUCONEST mid-single digits and Joenja acceleration post-VUS resolution.

**【CCO Stephen Toor - Product Performance】**
- RUCONEST: 11% prescriber base expansion, 97% attack resolution rate, positioned as "go-to" for severe HAE patients.
- Joenja: 65% Q4 growth, 40% US pipeline conversion, pediatric label expected in 2026, and UK launch pending NICE approval.
- Leniolisib pipeline expansion: Phase 2 trials for CVID (blockbuster potential) and APLS, with 2025 OpEx guidance of $30 million for Abliva integration.

**【CMO Anurag Relan - R&D Updates】**
- VUS resolution program: 1,200+ US patients with genetic variants, mid-2025 reclassification expected to expand APDS population.
- Pediatric Joenja trial: 60+ US patients, safety/tolerability data supports 2026 FDA filing.
- KL1333: 30,000 addressable mitochondrial disease patients in US/Europe, pivotal trial with FDA-agreed endpoints.

**【CFO Jeroen Wakkerman - Financials】**
- Q4 2024: $82.9 million revenue (+14% YoY), $5.6 million operating profit, $1.2 million net profit vs. $1.7 million loss in 2023.
- 2024 full-year: $297 million revenue, $12.8 million operating profit, $10.5 million net loss (vs. $23.5 million loss in 2023).
- 2025 OpEx: Flat at 2024 levels ($112 million) + $30 million Abliva-related costs.
- Cash: $132 million (Q4 2024), supporting 2025 growth initiatives.

**【Q&A Highlights】**
- **Tariff Risk**: Monitoring US drug tariffs, no inventory buildup planned; sufficient US stock for 2025 needs.
- **RUCONEST Competition**: New entrants may expand market, but RUCONEST's broad efficacy and patient loyalty maintain leadership.
- **CVID Development**: Phase 2 trial expected to inform Phase 3 design, seeking FDA fast-track designation for rare disease.
- **Abliva Integration**: $17 million R&D spend in 2025, with KL1333 pivotal trial resumption pending regulatory alignment.


Actual	0.015	0.05	0.215	-0.205	-0.17	0.01	0.005	-0.04	-0.19	-0.02	-0.02	0.05	-0.22	0.06	0.1	0.07
Forecast	0.0035	-0.06	0.09	0.055	-0.065	-0.0967	-0.13	0.0045	0.007	-0.002	-0.0025	0.019	-0.025	-0.105	0.0045	0.015
Surprise	+328.57%	+183.33%	+138.89%	-472.73%	-161.54%	+110.34%	+103.85%	-988.89%	-2814.29%	-900.00%	-700.00%	+163.16%	-780.00%	+157.14%	+2122.22%	+366.67%

PHAR

PHAR fundamentals

PHAR Q4 2025 Earnings

Earnings Call

You can ask Aime

PHAR

PHAR fundamentals

PHAR Q4 2025 Earnings

Earnings Call

PHAR Earnings Call Summary for Q4/20258:30 AM on Mar 12, 2026

PHAR Earnings Call Summary for Q3/20257:30 AM on Nov 6, 2025

PHAR Earnings Call Summary for Q2/20257:30 AM on Jul 31, 2025

PHAR Earnings Call Summary for Q1/20257:30 AM on May 8, 2025

PHAR Earnings Call Summary for Q4/20241:00 PM on Mar 13, 2025

You can ask Aime